Biochemistry–

Career Development Program


Word Icon Download Application

K12 HL089989 – Stanford Career Development Program in the Genetics and Genomics of Lung Diseases

Sponsored by National Institutes of Health (NIH)
RFA-HL-07-004 (http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-07-004.html)

Our Mission

We seek to develop a multidisciplinary career development program that will equip new MD or PhD investigators with the knowledge and skills to identify mutations which cause or are predisposed to lung diseases and to elucidate the roles of the affected genes in the etiology and pathogenesis of the diseases.  Our program emphasizes the genetics and genomics of lung development; in particular, genes that encode components of signaling pathways that control important steps in the lung development program, and how defects in such genes and pathways can cause or contribute to lung disease.  We train Scholars in state-of-the-art technologies in mouse as well as human genetics and genomics to allow them to move back and forth between a tractable model genetic organism (mouse) where they can more easily identify new components of pathways and determine their functions in lung development and disease, and the more challenging but clinically important human genetic and genomic studies. 

Major Program Components

Innovative Program Features

Program Personnel

Department of Biochemistry - Professor and Chairman
Investigator of the Howard Hughes Medical Institute

Over the past 15 years, Dr. Krasnow’s lab has carried out pioneering genetic and genomic analyses of the development of the Drosophila tracheal (respiratory) system.  His lab described the normal development process down to the level of individual cells, carried out genetic studies that identified over a hundred genes required for the process, and mapped, cloned and molecularly characterized several dozen of the genes and elucidated their roles in the developmental program.  Genomic studies over the past few years have begun to define the complete molecular program of the early stages of tracheal system development.  His work has made the tracheal system one of the best if not the best understood organogenesis programs at the genetic and molecular level, and has established the tracheal system as the premier genetic system for analyzing branching morphogenesis.  Indeed, it is the paradigm for current genetic studies of mammalian lung development. 

Six years ago, he began setting the foundation for a similar genetic and genomic analysis of mouse lung development.  An MD/PhD student, Ross Metzger, has carried out a systematic analysis of the airway and vascular branching process during early mouse lung development and described virtually the complete branching process during the first seven generations of branching.  He has also identified the first mutants that alter the pattern of airway and vascular branching in defined ways, and mapped one of the identified loci.  As his lab is preparing this work for publication, Dr. Krasnow has been invited to present the results at several major meetings and received wide acclaim.  His presentations include keynote lectures at the recent Biology of Shape meeting sponsored by Cell Press and the NHLBI Strategic Planning Meeting on Development of Early Origins of Lung Disease, and plenary lectures at this year’s annual meetings of the Society for Developmental Biology and the American Thoracic Society.  As Dr. David Warburton, a professor at USC and a leader in the lung development field proclaimed, "The work is going to rewrite the textbooks on lung development".  In parallel, a postdoctoral fellow, Dr. Hernan Espinoza, and two research assistants, have conducted a large scale in situ hybridization screen for genes that are expressed during this period to identify genes that are likely to control the branching events. They have determined the spatial patterns of expression of over 2000 mouse genes in the early mouse lung, including all 1000 of the known and predicted ligand and receptor genes in the genome except for odorant receptors.  They found 44 ligand genes and 51 receptors with localized expression patterns, which represent most and possibly all of the localized signaling and receiving centers in the early mouse lung.  These signaling pathways presumably control the morphogenesis and cell differentiation events in early mouse lung development, including pulmonary vascular development, of which others in the lab are currently studying. 190 other genes were found with spatially restricted expression patterns in the developing lung, genes that are presumably regulated by the signaling pathways. Another postdoctoral fellow, Dr. Maya Kumar, has developed a strategy using Cre recombinase and GFP and dsRED transgenes genes for generating fluorescently-marked clones of cells in the lung.  This has allowed her to probe the proliferative and migratory behavior and the developmental potential of individual lung cells and their progeny, at many different positions within the lung and at different stages of development, including cells that contribute to formation of the pulmonary vessels.  Clonal analysis has been a powerful tool for addressing similar issues in organ development in Drosophila, but it has not gained widespread use in other animals because of the technical challenges in making and marking cell clones.  Dr. Kumar's success demonstrates that those technical challenges can be overcome in the lung and opens the way to an analysis of lung and pulmonary vascular development at the cellular level.

Department of Pediatric Cardiology – Dwight and Vera Dunlevie Professor
Wall Center for Pulmonary Vascular Diseases – Research Director

Dr. Rabinovitch’s research has focused on cell extracellular matrix interactions in vascular development and diseases. The identification of the pivotal role of a serine elastase in cardiovascular disease led to pharmacological and gene therapy approaches to utilize elastase inhibitors experimentally to prevent pulmonary hypertension, post cardiac transplant coronary artery disease and graft rejection, myocarditis, myocardial ischemia, vein graft atherosclerosis, and restenosis. She has also shown that elastase inhibitors can induce regression of pulmonary vascular disease.  Current studies relate to the use of genetically modified mice to address the mechanisms whereby genetic and environmental factors interact in the development of pulmonary vascular disease, focusing on the bone morphogenetic protein receptor signaling pathway, the serotonin receptor and transporter, and the interaction between the calcium-binding protein, S100A4/Mts-1 and the RAGE receptor. Her work on cross talk between matrix and growth factor receptors has established a new paradigm in the regulation of cell proliferation, migration and propensity to apoptosis.  Her current program focuses on understanding cross-talk between the BMP receptors (II and Ia), and other signaling pathways including those responsive to the S100 proteins and Wnts.  She is characterizing the impact of aberrant BMP mediated signaling on transcription factors and on target genes both in cultured cells and in transgenic mice with targeted aberrations in BMP signaling in endothelial or smooth muscle cells.  A new direction of her program investigates host susceptibility in viral-mediated severe pulmonary vascular occlusive disease.  In addition to leading a basic research program, Dr. Rabinovitch initiated clinical studies related to the assessment of pulmonary hypertension, and a clinical trial testing the efficacy of elastase inhibitors in the prevention of bronchopulmonary dysplasia.  Dr. Rabinovitch maintains clinical responsibilities as ward attending in Pediatric Cardiology and actively consults and reviews cases of pulmonary hypertension patients both locally and internationally.

Dr. Rabinovitch has received numerous research awards including the Research Achievement Award of the Canadian Cardiovascular Society, the Comroe Lectureship of the American Physiological Society, the Paul Dudley White Lectureship of the AHA, the award of merit from the Heart and Stroke Foundation of Canada, the Distinguished Scientist Award from the CIHR, and the Gill Award for Outstanding Contribution to Cardiovascular Research.  In 2004 she was the Distinguished Lecturer of the CIHR at the Canadian Cardiovascular Society Annual Meeting and was awarded the Prize in Basic Science by the AHA. Dr. Rabinovitch was the summarizer of the 2004 Aspen Lung Conference on pulmonary hypertension.  In 2005, she was the Dickinson Richards Lecturer at the AHA and in 2006 received the Distinguished Scientist Award of the AHA.

Departments of Genetics and Pediatrics – Professor

Dr. Francke has expertise in human genetics and an outstanding record of mentorship in her own lab.  She served as Director of the Postdoctoral Training Program in Medical Genetics at Stanford from 1991-2005.  She was President of the American Society of Human Genetics in 1999 and received the Sanders Award in Genetics from the March of Dimes Foundation in 2001.  She has served on numerous genetic and genomic advisory boards including Chairman of the NIH Human Genetics Study Section (1992-94) and currently is on the Scientific Advisory Board of the Austrian Genome Project.  She is a member of the American Academy of Arts and Sciences and a fellow of the American Association for the Advancement of Science.  Her current research focuses on human multilocus deletion and chromatin modification syndromes and their mouse models including Rett syndrome, Williams-Beuren syndrome, and Prader-Willi.  Mouse models for all 3 disorders have been generated and are used for global gene expression and regulation studies.

Department of Developmental Biology – Professor
Investigator in the Howard Hughes Medical Institute

Dr. Beachy recently arrived from Johns Hopkins University where he was Professor of Biochemistry and Molecular Biology.  He has pioneered research in genetic and genomic analysis of Hedgehog signaling pathways in mouse development and human disease and has an outstanding record as a mentor.  He discovered the Hedgehog family of signaling molecules and has elucidated their novel processing and biogenesis pathway, mechanism of action, and signal transduction pathways, and their roles in human disease, using genetic and genomic approaches.  His recent work includes important advances in the roles of alterations in Hedgehog signaling in lung cancer and repair.  He is a member of the National Academy of Sciences. 

Department of Pediatrics/Cardiopulmonary Research Program
Division of Neonatal and Developmental Medicine – Professor

Dr. Bland was recruited to Stanford in 2002 from University of Utah School of Medicine where he was Fields Professor of Pediatrics and Director of the Division of Lung Biology. Dr Bland’s research has focused on lung fluid balance during development and on the pathogenesis and treatment of acute and chronic neonatal lung injury.  He has been an Established Investigator of the American Heart Association (1979-84), and received the Bruton Award for research on the role of plasma proteins in neonatal respiratory distress syndrome.  He also received the Distinguished Alumnus Award from Boston University School of Medicine (1996) and an Honorary Doctorate from Uppsala University (2004). Dr Bland's past trainees include more than a dozen physician-scientists who have held major university faculty appointments and who have garnered NIH research support.

Department of Medicine – Associate Professor
Division of Pulmonary and Critical Care Medicine – Chief

Dr. Rosen is director of the Interstitial Lung Disease Clinic at Stanford.  He is able to provide valuable pulmonary and mentoring perspectives as the Principle Investigator for the Stanford Pulmonary and Critical Care Medicine training grant.  His research interests are in the areas of apoptotic signaling in cancer and fibrotic lung disease.  His laboratory is examining mechanisms of resistance to apoptosis in lung cancer cells and a novel regulator they discovered of the unfolded protein response.  He is involved in translational research focusing on pre-clinical trials of novel Jun kinase inhibitors in pulmonary fibrosis and proteomic patterns in lung cancer and he is principal investigator on clinical trials of treatments for IPF.

Department of Biochemistry – Professor and Associate Chairman
Investigator in the Howard Hughes Medical Institute

Dr. Brown has been a pioneer in development of novel genetics and genomics technology for many years.  His is co-inventor of DNA microarrays and well known for his creative application of that technology to diverse biological problems including cell differentiation and cancer as well as other human diseases. His work has lead the transformation into the functional genomic era.  His laboratory is extremely collaborative and has promoted the free and wide dissemination of all the technologies they develop.  His group currently is involved in mapping the regulatory architecture and dissecting molecular mechanisms that control global gene expression programs, especially post-transcriptional mechanisms that control localization, translation and decay of RNAs; using defined ex vivo models and systematic studies of gene expression programs to investigate the pathogenesis of human cancer and development of new approaches to its detection diagnosis and treatment; and exploration and characterization of the microbial ecosystems of the human body.  He is also pursuing systematic approaches to analysis of signaling pathways in cultured cells, and has an ongoing project on lung cancer.

Department of Medicine/Pulmonary – Bass Professor
Center of Excellence in Pulmonary Biology in the Department of Pediatrics – Director

Dr. Cornfield recently arrived at Stanford from the University of Minnesota where he was interim head of the Department of Pediatrics. His research focuses on the fundamental role of oxygen (O2) in modulating perinatal pulmonary vascular tone. His lab demonstrated that smooth muscle cells (SMC) from the fetal pulmonary arteries (PA) directly sense changes in O2 tension and respond to acute hypoxia with an increase in free cytosolic calcium, and that pulmonary artery smooth muscle cell KCa channel activation mediates perinatal pulmonary vasodilation. Other work focuses on an analysis of the subcellular mechanisms whereby O2 causes pulmonary vasodilation and has identified novel regulators of ion channel expression in the perinatal pulmonary circulation. He has mentored 28 fellows, predoctoral, and postdoctoral students over the past 12 years, the vast majority of which are in academic medicine or basic science research.  He has also directed training programs in Pediatric Critical Care Medicine and Pulmonary Medicine, and served on the steering committee of the University of Minnesota's Medical Scientist Training Program. He received the faculty educator award eight times at the University of Minnesota and was twice recognized as Master Teacher of the Year and once as Clinician-Scientist of the year. He has been an Established Investigator of the American Heart Association (AHA) and has served as Chair of the AHA study section for Lung Biology.

Department of Developmental Biology – Professor

Dr. Kingsley uses genetic and genomic approaches to investigate mechanisms of skeletal development and evolution.  He has pioneered genetic and genomic approaches to mapping and cloning mouse genes involved in skeletal development, including the genetic and molecular genetic characterization of BMP signaling pathways.  He has analyzed the function of BMP genes in bone and joint formation and mapped many interesting cis-regulatory elements, including one that is specifically active in the mesenchyme of developing lung that is being developed as a new analytic tool in genetic studies of lung development with Krasnow’s lab. His group is also single handedly responsible for developing the Threespine stickleback, a fish species of the Northern hemisphere with a rich history of population genetic and ecological research, into a genomic model organism.  He has used stickleback genetics and genomics to study selection on morphological characters and to identify loci that are responsible for phenotypic variation and identify the individual mutations that lead to changes in skeletal anatomy during vertebrate evolution.  This work foreshadows how developmental biology, genomics, and human genetics will combine in the future to identify human variants responsible for morphological and physiological differences among us.

Department of Developmental Biology – Professor
Investigator of the Howard Hughes Medical Institute

Dr. Nusse discovered Wnt proteins and has made major contributions to the biochemical, genetic and genomic analysis of Wnt proteins and their signaling pathways. His work has also provided important insights into the function of Wnt signaling pathways in development, stem cell regulation and function, and disease. Recent work includes analysis of Wnt pathway reporter genes and Wnt pathway function in mouse lung, which suggest a potential role for the pathway in lung stem cell niches. They are also interested in the effects of Wnt proteins on neural stem cells and embryonic stem cells.  He is an elected member of the American Academy of Arts and Sciences.

Department of Medicine/Pulmonary and Critical Care Medicine – Associate Professor
Wall Center for Pulmonary Vascular Disease – Co-Director

Dr. Doyle is also the Director of the Adult Pulmonary Hypertension Clinical Service that follows a significant population of pulmonary hypertension patients in all stages of disease: from recently diagnosed and/or maintained on drug therapies to post transplantation.  She has participated in numerous clinical and experimental studies related to pulmonary hypertension and lung transplantation and has been the Stanford PI for several multi-center clinical trials to evaluate therapies for pulmonary hypertension.  Dr. Doyle has also been integral in the development of a database for pulmonary hypertension patients.  She is the Director for a clinical fellowship in pulmonary vascular disease as well as the Program Director for the Stanford Fellowship program in Pulmonary and Critical Care Medicine. Dr. Doyle is active in the pulmonary hypertension community and lectures on pulmonary hypertension locally and internationally.  She served on the ACCP Consensus Panel which developed Evidence Based Clinical Practice Guidelines for which were published in 2004 and is currently a member of the Pulmonary Hypertension Association’s Scientific Leadership Council.  

Department of Pediatrics – Associate Professor

Dr. Feinstein has Masters Degrees in both engineering and public health.  He is an interventional pediatric cardiologist with a broad understanding of clinical and bioengineering science.  He is Director of the Wall Center for Pulmonary Vascular Disease and Associate Director for Pediatric and Congenital Cardiac Catheterization.  He has been responsible for the care of pediatric patients with pulmonary hypertension and for catheter studies on both pediatric and adult pulmonary hypertension patients.  Dr. Feinstein maintains a growing pediatric pulmonary hypertension practice, with patients ranging in age from newborn to late teens with the full spectrum of pulmonary hypertension disease.  Dr. Feinstein has served as local PI and Co-PI for several clinical studies of pulmonary hypertension that have included or focused on pediatric patients and for clinical trials of chronic vasodilator therapy.  One of Dr. Feinstein's most innovative research projects is the cross-disciplinary investigation of the complex blood flow characteristics in the pulmonary circulation in collaboration with Dr. Charles Taylor. 

Department of Biochemistry – Associate Professor

Dr. Harbury’s lab engineers proteins and small-molecule drugs at atomic resolution through a combination of structural calculations and combinatorial library synthesis. Their goal is to elucidate predictive principles by which novel shapes and catalytic properties can be conferred accurately on designed polypeptides.

Department of Medicine/Pulmonary and Critical Care Medicine – Associate Professor

Dr. Kao’s research interests are in lung inflammation and hypertensive pulmonary vascular disease.  In collaboration with Dr. Ronald Pearl’s laboratory in the Department of Anesthesia, Dr. Kao has studied the pathogenenis of pulmonary hypertension.  They have created rat and mice models of experimental pulmonary hypertension that accurately reproduce the physiology and pathology of human primary pulmonary hypertension.  His group used the rat model to demonstrate the efficacy of statins in reversing severe experimental pulmonary hypertension, and demonstrated that simvastatin treatment served to increase expression of bone morphogenetic protein receptor type II in lung microvascular endothelial cells and smooth muscle cells.  Dr. Kao has translated this discovery into an observational human case series. A randomized placebo-controlled trial of simvastatin has been initiated at Stanford and there is interest in pursuing a multicenter randomized control trial of statins in pulmonary hypertension. Dr. Kao is also pursuing studies of the role of mast cells and of mutations in bone morphogenetic protein receptor type II in the pathogenesis of experimental pulmonary hypertension.

Department of Pediatrics – Professor and Chairman
Lucile Packard Children's Hospital – Adalyn Jay Physician in Chief

Dr. O'Brodovich attended the University of Manitoba where he obtained his medical degree and training in pediatrics and pediatric respiratory medicine. He subsequently completed a three-year pulmonary research fellowship at Columbia University in New York before returning to Canada in 1981 as an assistant professor at McMaster University in Hamilton, Ontario. In 1986 he moved to SickKids where he subsequently became a senior scientist, Division Chief of Respiratory Medicine, and Head of the SickKids Research Institute's Division of Respiratory Research. From 1996-2006 he was the Chair of Paediatrics at the University of Toronto and the Paediatrician in Chief at the Hospital for Sick Children (SickKids).

Dr. O'Brodovich, his trainees, research associate and collaborators wish to develop new therapies for the neonatal and adult (acute) respiratory distress syndromes (RDS) and heart failure induced (cardiogenic) pulmonary edema.  Present studies are investigating the effect of lung maturity, mediators and hormones on the pre and post-translational regulation of the epithelial Na+ channel (ENaC) and Na and fluid transport by the healthy and edematous non-primate mammalian and human lung.

Department of Medicine/Pulmonary and Critical Care Medicine – Associate Professor

Dr. Nicolls’s lab focuses primarily on the contribution of the immune response to lung disease. They are specifically examining the contribution of inflammation to the development of pulmonary hypertension. They also study how airway remodeling occurs in transplantation with specific respect to the microvascular circulation and to the initiation of fibroproliferation.

Department of Medicine/Pulmonary and Critical Care Medicine – Assistant Professor

Dr. Zamanian is interested in:  1) The Utility of S100A4/Mts1 as a Biomarker in Pulmonary Arterial Hypertension (PAH); 2) Prevalence and Treatment of Insulin Resistance in PAH; 3) The Effect of EGF-Receptor Blockade and Elastase Inhibitor on Pulmonary Arteries of Patients with PAH; 4) Characterization of Pulmonary Arteries in Patients with Idiopathic and Secondary PAH by Wedge Angiography; and 5) The Optimal Angle for Angiographic Evaluation of the Left Pulmonary Artery in Patients with PAH.

Departments of Medicine/Oncology and Biochemistry – Professor

Dr. Chu is an innovator in DNA microarray use and analysis and an expert in biostatistics.  He will conduct workshops to instruct Scholars in the preparation, use and analysis of microarrays and serve as special genomics consultant to the Scholars during their mentored research projects.

Types of Trainees

Throughout the training period, both the MD Scholars and PhD Scholars will participate in inter-group lab meetings, journal clubs, and seminars aimed at enhancing their understanding of genetic and genomic concepts and advances in pulmonary biology, and at facilitating interactions between the genetic, genomic, and pulmonary communities at Stanford.

MD Scholars – Timeline for Training

Molecular Foundations of Medicine (preparation for the core curriculum, if needed)
Molecular Biology/Genomics (Biochem 205)
Human Genetics (Genetics 202)
Cell Biology/Signaling (Theriot/Nelson)
Meet with Program Directors to obtain Program overview

Advanced Genetics (Genetics 203) 4 units
Computational Molecular Biology (Biochem 218). (Doug Brutlag) 3 units
Frontiers in Biological Research (Genetics/Biochem/DevBio 215) 1 unit
Begin meeting with potential Mentors

Genomics (Genetics 211) 3 units
Signal Transduction Pathways and Networks (MPHA 210) 4 units
Frontiers in Biological Research (Genetics/Biochem/DevBio 215) 1 unit
Continue meeting with potential Mentors and Co-Mentors

The eucaryote chromosome (Structural Biology 229) 3 units – OR – Advanced Molecular Biology (Biochem 202) 4 units
Developmental Biology (Development Biology 210) 5 units
Begin didactic training:
Statistics for Research (Biomedical Informatics 303) 1 unit
Current Concepts and Dilemmas in Genetic Testing (Genetics 238) 2 units
Decide on Mentor and Co-Mentor

Complete didactic training (SPECTRUM)
Responsible Conduct of Research (Medicine 255) 1 unit
Investigate research opportunities and select research Mentor and Co-Mentor 
Formulate mentored research proposal and present to Advisory Committee
Meet with Mentor at least twice monthly and Co-Mentor quarterly
Meet with Advisory Committee for annual evaluation

Conduct mentored research project
Participate in Frontiers in Biology seminars
Participate in Cardiopulmonary Research in Progress seminar series
Participate in quarterly intergroup Career Development Program meeting (give one journal club and one data presentation)
Scientific Writing for Basic and Translational Scientists (HRP215) 2-3 units
Attend lab meetings
Attend national meeting
Meet with Mentor at least twice monthly and Co-Mentor quarterly
Meet with Advisory Committee for annual evaluation

Complete mentored research project
Write paper(s) on research project
Attend and present work at national meeting
Participate in Frontiers in Biology seminars
Participate in Cardiopulmonary Research in Progress seminar series
Participate in quarterly intergroup Career Development Program meeting (give one journal club and one data presentation)
Attend lab meetings
Meet with Mentor at least twice monthly and Co-Mentor quarterly
Meet with Advisory Committee for annual evaluation
Plan future career path and prepare proposal for a K08, K23, R01, or similar grant application.
Exit interview with Program Director

PhD Scholars – Timeline for Training

First year medical school courses in pulmonary anatomy and histology 
Molecular Foundations of Medicine (individual sections, as needed to fill in deficiencies)
Meet with Program Directors to obtain Program overview

Genomics (Genetics 211) 3 units
Signal Transduction Pathways and Networks (MPHA 210) 4 units
Frontiers in Biological Research (Genetics/Biochem/DevBio 215) 1 unit
Begin meeting with potential Mentors and Co-Mentors

Genomics (Genetics 211) 3 units
Signal Transduction Pathways and Networks (MPHA 210) 4 units
Frontiers in Biological Research (Genetics/Biochem/DevBio 215) 1 unit
Continue meeting with potential Mentors and Co-Mentors

The eucaryote chromosome (Structural Biology 229) 3 units – OR – Advanced Molecular Biology (Biochem 202) 4 units
Developmental Biology (Development Biology 210) 5 units
Begin didactic training:
Statistics for Research (Biomedical Informatics 303) 1 unit
Current Concepts and Dilemmas in Genetic Testing (Genetics 238) 2 units
Decide on Mentor and Co-Mentor
Human Health and Disease I (Medicine/Inde 221) pulmonary anatomy and pathophysiology

Complete didactic training (as necessary)
Clinical rotations in Neonatology, Pediatric Pulmonary Medicine, and Adult Pulmonary Medicine
Responsible Conduct of Research (Medicine 255) 1 unit.
Investigate research opportunities and select research Mentor and Co-Mentor 
Formulate mentored research proposal
Meet with Mentor at least twice monthly and Co-Mentor quarterly
Meet with Advisory Committee for annual evaluation

Conduct mentored research project
Participate in Frontiers in Biology seminars
Participate in Cardiopulmonary Research in Progress seminar series
Participate in quarterly intergroup Career Development Program meeting (give one journal club and one data presentation)
Scientific Writing for Basic and Translational Scientists (HRP215) 2-3 units
Attend lab meetings
Attend national meeting
Meet with Mentor at least twice monthly and Co-Mentor quarterly
Meet with Advisory Committee for annual evaluation

Complete mentored research project
Write paper(s) on research project
Attend and present work at national meeting
Participate in Frontiers in Biology seminars
Participate in Cardiopulmonary Research in Progress seminar series
Participate in quarterly intergroup Career Development Program meeting (give one journal club and one data presentation)
Attend lab meetings
Meet with Mentor at least twice monthly and Co-Mentor quarterly
Meet with Advisory Committee for annual evaluation
Plan future career path and prepare proposal for a K08, K23, R01, or similar grant application.
Exit interview with Program Director

Requirements

Scholars must be citizens or non-citizen nationals of the United States (US), or must be lawfully admitted to the US for permanent residence (ie. in possession of a currently valid Alien Registration Receipt Card I-155 or other legal verification of such status).  Individuals on temporary visas are not eligible.

At least 75% of a Scholar’s full-time professional effort must be devoted to this program and the remainder devoted to clinical and teaching pursuits consonant with the objectives of this award.  Scholars must not be or have been a Principal Investigator on an R01 or R21 award or on a component project of a Program Project (P01), Center grant (P50, P60, or U54), mentored career development (K-series) grant, or other equivalent research grant award.  Scholars may have had support on a NRSA grant (F or T) or NIH small grant (R03).

Scholars must be Research Fellows, Clinical or Research Instructors, or recently-appointed Assistant Professors who have completed their MD or PhD degree(s) within the past 5 years and are committed to the study of lung diseases.  A Stanford University appointment is required (This is a separate appointment process handled through your Stanford Department).  

Scholars must commit to a minimum of 2 years of career development in this K12 program (preferably 3 years to complete training).

Application Instructions

Stanford University believes that a Fellowship Program composed of individuals who are both highly qualified and diverse in terms of culture, gender, race, ethnicity, background, work and life experiences, skill, and interests is essential to the postgraduate education of scientists and physicians.  Because of our strong belief in the value of diversity, we especially encourage applications from African-Americans, Hispanics, Native Americans, Alaskan Natives, and Pacific Islanders, as well as those who have disabilities or come from a disadvantaged background, whose backgrounds and experience provide additional dimensions that will enhance the Stanford Career Development Program in the Genetics and Genomics of Lung Diseases.

Candidates must submit:

Evaluation of Candidates:

Contacts

Joella Ackerman
Student and Postdoctoral Affairs Administrator
Department of Biochemistry - Stanford University
Beckman B400
279 Campus Drive West
Stanford, CA  94305-5307
joella.ackerman@stanford.edu

 

 

 

Stanford Medicine Resources:

Footer Links: